# Matthew A Marx

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8306772/publications.pdf

Version: 2024-02-01

| | | | |
|---|---|---|---|
| 21 papers | 2,118 citations | 430874 18 h-index | 713466 21 g-index |
| 25 all docs | 25 docs citations | 25 times ranked | 2817 citing authors |

| # | Article | IF | Citations |
|---|---|---|---|
| 1 | The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients. Cancer Discovery, 2020, 10, 54-71. | 9.4 | 820 |
| 2 | Identification of the Clinical Development Candidate MRTX849, a Covalent KRAS<sup>G12C</sup> Inhibitor for the Treatment of Cancer. Journal of Medicinal Chemistry, 2020, 63, 6679-6693. | 6.4 | 300 |
| 3 | Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS<sup>G12D</sup> Inhibitor. Journal of Medicinal Chemistry, 2022, 65, 3123-3133. | 6.4 | 243 |
| 4 | Design and SAR of thienopyrimidine and thienopyridine inhibitors of VEGFR-2 kinase activity. Bioorganic and Medicinal Chemistry Letters, 2004, 14, 21-24. | 2.2 | 91 |
| 5 | Synthetic Design for Combinatorial Chemistry. Solution and Polymer-Supported Synthesis of Polycyclic Lactams by Intramolecular Cyclization of Azomethine Ylides. Journal of the American Chemical Society, 1997, 119, 6153-6167. | 13.7 | 83 |
| 6 | Total Synthesis of (+)-Ambruticin S. Journal of the American Chemical Society, 2001, 123, 12432-12433. | 13.7 | 70 |
| 7 | Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design. MedChemComm, 2010, 1, 139. | 3.4 | 68 |
| 8 | Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity. ACS Medicinal Chemistry Letters, 2018, 9, 1230-1234. | 2.8 | 65 |
| 9 | Design of Selective, ATP-Competitive Inhibitors of Akt. Journal of Medicinal Chemistry, 2010, 53, 4615-4622. | 6.4 | 64 |
| 10 | Total synthesis of (+)-ambruticin S. Tetrahedron, 2003, 59, 6819-6832. | 1.9 | 56 |
| 11 | Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design. ACS Medicinal Chemistry Letters, 2013, 4, 91-97. | 2.8 | 54 |
| 12 | 4-Methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 6096-6099. | 2.2 | 31 |
| 13 | Discovery of Novel, Potent, and Selective Inhibitors of 3-Phosphoinositide-Dependent Kinase (PDK1). Journal of Medicinal Chemistry, 2011, 54, 8490-8500. | 6.4 | 30 |
| 14 | Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical Utility. PLoS ONE, 2015, 10, e0138616. | 2.5 | 30 |
| 15 | Highly Selective and Potent Thiophenes as PI3K Inhibitors with Oral Antitumor Activity. ACS Medicinal Chemistry Letters, 2011, 2, 809-813. | 2.8 | 29 |
| 16 | Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Proteinâ€“Protein Interaction. Journal of Medicinal Chemistry, 2022, 65, 9678-9690. | 6.4 | 29 |
| 17 | Divergence between the enzyme-catalyzed and noncatalyzed synthesis of 3-dehydroquinate. Journal of Organic Chemistry, 1994, 59, 2082-2085. | 3.2 | 22 |
| 18 | Small-molecule, tubulin-binding compounds as vascular targeting agents. Expert Opinion on Therapeutic Patents, 2002, 12, 769-776. | 5.0 | 21 |

| # | Article | IF | Citations |
|---|---|---|---|
| 19 | Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumors. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 3059-3063. | 2.2 | 10 |
| 20 | 2-Morpholino-4-oxo-4,5-dihydrothiophene-3-carbonitrile. Acta Crystallographica Section E: Structure Reports Online, 2009, 65, o2765-o2765. | 0.2 | 1 |
| 21 | Abstract LB-098: The anti-tumor activity of the KRAS G12C inhibitor MRTX849 is augmented by cetuximab in CRC tumor models. , 2020, , . | | 0 |